Market Overview
The global kidney cancer therapeutics and diagnostics market was valued at USD 5.37 Billion in 2024 and is projected to reach USD 9.24 Billion by 2033, growing at a CAGR of 5.90% during the forecast period of 2025-2033. North America dominated the market in 2024 with over 35.4% share. Rising kidney cancer incidences, an aging population, and supportive government initiatives are driving demand for advanced diagnostics and personalized treatments. The market includes therapeutic drugs, diagnostics, and innovative technologies to enhance early detection and treatment outcomes.
Study Assumption Years
- Base Year: 2024
- Historical Years: 2019-2024
- Forecast Years: 2025-2033
Kidney Cancer Therapeutics and Diagnostics Market Key Takeaways
- The global market size was USD 5.37 Billion in 2024, with a forecast to reach USD 9.24 Billion by 2033.
- The CAGR during 2025-2033 is estimated at 5.90%.
- North America accounted for over 35.4% market share in 2024.
- Key factors driving growth include rising kidney cancer cases, increasing geriatric population, and government awareness initiatives.
- Drugs dominate the market with approximately 84.3% share in 2024.
- Clear cell RCC leads cancer types with around 66.3% market share.
- Hospitals hold approximately 40.0% of the application segment market share in 2024.
Sample Request Link: https://www.imarcgroup.com/kidney-cancer-therapeutics-diagnostics-market/requestsample
Market Growth Factors
Kidney cancer cases increasing around the world are the main reason for the kidney cancer therapeutics and diagnostics market. International Kidney Cancer Coalition (IKCC) states nearly 431,000 new kidney cancer cases occur each year around the world. This creates a demand for better diagnostic and therapeutic options for treatment of the population. The geriatric population increases, with smoking, obesity and high blood pressure further contributing factors do so to this market. The American Cancer Society reports that in developed countries like the United States, over 81,610 new prostate cancer cases occurred in 2024. Most cases were found in people over 65.
The trend also grows because advanced diagnostic and therapeutic tools expand with diagnosing using biomarkers, biopsying liquid, and imaging through positron emission tomography/computed tomography (PET/CT) scans, which can detect and stage disease before. Therapeutics moving toward the vascular endothelial growth factor pathway for example tyrosine kinase inhibitors like sunitinib and pazopanib and immune checkpoint inhibitors such as pembrolizumab and nivolumab has caused better management of mRCC. Regulatory authorities such as Health Canada have approved immune checkpoint inhibitors for adjuvant treatment of RCC since as early as 2022.
High investment as well as research efforts drive market growth. Large-scale funding, such as the grants from the National Cancer Institute, is supporting the kidney cancer research and development of newer diagnostics as well as therapeutics. In 2022, as part of the funding to find new biomarkers and therapeutics supporting the study of the ATF4 protein in clear cell renal cell carcinoma, the Department of Defense's Kidney Cancer Research Program (DOD KCRP) awarded Weill Cornell Medicine a USD 1 million grant. Public-private partnerships can support the further development of these therapeutics and diagnostics.
Market Segmentation
By Component:
- Drugs: Holding approximately 84.3% market share in 2024, drugs lead due to their high efficacy and reduced side effects from targeted therapies and immunotherapies. Key targeted drugs include TKIs like sunitinib and pazopanib and immunotherapies such as pembrolizumab and nivolumab. Continuous R&D and combination therapies drive this segment.
- Diagnostics: Includes imaging tests, biopsy, blood tests, and others focused on early diagnosis and disease staging.
By Cancer Types:
- Clear Cell RCC: Leading with around 66.3% market share in 2024, characterized by high lipid and glycogen clear cells. Its advanced-stage diagnosis and poor prognosis drive demand for targeted therapies and personalized treatment.
- Papillary RCC
- Chromophobe RCC
- Transitional Cell Carcinoma
- Others
By Application:
- Hospitals: Leading with approximately 40.0% market share in 2024, hospitals dominate due to infrastructure supporting diagnosis (imaging, biopsies) and treatment modalities such as surgery, radiation, targeted therapies, and immunotherapy by multidisciplinary teams.
- Pharmaceutical Labs
- Genomic Laboratories
- Others
Regional Insights
North America led the kidney cancer therapeutics and diagnostics market in 2024 with a share of 35.4%, driven by the United States holding 89.60% of the regional share. The region benefits from a high prevalence of kidney cancer, advanced healthcare infrastructure, substantial research and development investments, and access to diverse treatment options including targeted therapy and immunotherapy. Early detection programs and growing awareness contribute to North America's dominant position in the market.
Recent Developments & News
- September 2023: A global diagnostics company partnered with a major South African firm to accelerate early kidney cancer diagnosis by promoting liquid biopsy and biomarker testing technologies in underserved African regions.
- August 2023: A multinational pharmaceutical company launched a new immunotherapy medication for renal cell carcinoma in the UAE, marking advancement in precision therapies in the Middle East.
- June 2023: A leading health technology company introduced AI-based imaging technology for enhanced kidney cancer diagnosis across the Middle East using deep learning algorithms for precise tumor detection.
Key Players
- Bristol-Myers Squibb Company
- Exelixis Inc.
- Genentech Inc. (Roche Holding AG)
- Novartis AG
- Pfizer Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request For Customization: https://www.imarcgroup.com/request?type=report&id=7528&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
Comments (0)